EntryPoint Capital’s Emergent Biosolutions EBS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$87.1K Sell
10,390
-4,187
-29% -$35K 0.02% 751
2026
Q1
$121K Buy
+14,577
New +$151K 0.04% 692
2025
Q3
Sell
-43,220
Closed -$276K 729
2025
Q2
$276K Buy
+43,220
New +$247K 0.14% 323
2024
Q4
Sell
-20,980
Closed -$175K 790
2024
Q3
$175K Buy
+20,980
New +$191K 0.1% 498

Other funds holding EBS

EntryPoint Capital's EBS Position: Q2 2026 in Review

EntryPoint Capital reduced its Emergent Biosolutions (EBS) stake by 29% in Q2 2026, selling an estimated $35K and leaving 10,390 shares worth $87.1K. The position accounts for 0.02% of the portfolio, ranked #751.

EntryPoint Capital first reported a position in EBS in Q3 2024 and has held it in 4 quarters since. The position peaked at $276K in Q2 2025. 195 funds tracked by Wall St. Rank hold EBS as of Q2 2026.

  • EntryPoint Capital held 10,390 shares of Emergent Biosolutions worth $87.1K as of Q2 2026.
  • EntryPoint Capital sold 4,187 Emergent Biosolutions shares in Q2 2026, an estimated $35K.
  • Emergent Biosolutions made up 0.02% of EntryPoint Capital's portfolio in Q2 2026, its #751 holding.
  • EntryPoint Capital first reported a position in Emergent Biosolutions in Q3 2024 and has held it in 4 quarters since.
  • EntryPoint Capital's Emergent Biosolutions position peaked at $276K in Q2 2025.
  • 195 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.